[go: up one dir, main page]

WO2007038720A3 - Modulation of tlr-mediated immune responses using adaptor oligonucleotides - Google Patents

Modulation of tlr-mediated immune responses using adaptor oligonucleotides Download PDF

Info

Publication number
WO2007038720A3
WO2007038720A3 PCT/US2006/037987 US2006037987W WO2007038720A3 WO 2007038720 A3 WO2007038720 A3 WO 2007038720A3 US 2006037987 W US2006037987 W US 2006037987W WO 2007038720 A3 WO2007038720 A3 WO 2007038720A3
Authority
WO
WIPO (PCT)
Prior art keywords
tlr
modulation
immune responses
mediated immune
adaptor oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/037987
Other languages
French (fr)
Other versions
WO2007038720A2 (en
Inventor
Marion Jurk
Joerg Vollmer
Arthur M Krieg
Eugen Uhlmann
Bernhard O Noll
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coley Pharmaceutical GmbH
Coley Pharmaceutical Group Inc
Original Assignee
Coley Pharmaceutical GmbH
Coley Pharmaceutical Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coley Pharmaceutical GmbH, Coley Pharmaceutical Group Inc filed Critical Coley Pharmaceutical GmbH
Priority to AU2006294528A priority Critical patent/AU2006294528A1/en
Priority to EA200800943A priority patent/EA200800943A1/en
Priority to JP2008533635A priority patent/JP2009510096A/en
Priority to EP06836152A priority patent/EP1928500A2/en
Priority to BRPI0616770-5A priority patent/BRPI0616770A2/en
Priority to CA002623764A priority patent/CA2623764A1/en
Publication of WO2007038720A2 publication Critical patent/WO2007038720A2/en
Publication of WO2007038720A3 publication Critical patent/WO2007038720A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to the ability of certain oligonucleotides to modify the profile of TLR ligands such as TLR7, TLR8 and TLR9 ligands.
PCT/US2006/037987 2005-09-27 2006-09-27 Modulation of tlr-mediated immune responses using adaptor oligonucleotides Ceased WO2007038720A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2006294528A AU2006294528A1 (en) 2005-09-27 2006-09-27 Modulation of TLR-mediated immune responses using adaptor oligonucleotides
EA200800943A EA200800943A1 (en) 2005-09-27 2006-09-27 MODULATION OF TLR-MEDIATED IMMUNE RESPONSES WITH THE USE OF OLIGONUCLEOTIDE ADAPTERS
JP2008533635A JP2009510096A (en) 2005-09-27 2006-09-27 Modulation of TLR-mediated immune responses using adapter oligonucleotides
EP06836152A EP1928500A2 (en) 2005-09-27 2006-09-27 Modulation of tlr-mediated immune responses using adaptor oligonucleotides
BRPI0616770-5A BRPI0616770A2 (en) 2005-09-27 2006-09-27 modulation of tlr-mediated immune responses employing adapter oligonucleotides
CA002623764A CA2623764A1 (en) 2005-09-27 2006-09-27 Modulation of tlr-mediated immune responses using adaptor oligonucleotides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72098105P 2005-09-27 2005-09-27
US60/720,981 2005-09-27

Publications (2)

Publication Number Publication Date
WO2007038720A2 WO2007038720A2 (en) 2007-04-05
WO2007038720A3 true WO2007038720A3 (en) 2007-06-21

Family

ID=37900484

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/037987 Ceased WO2007038720A2 (en) 2005-09-27 2006-09-27 Modulation of tlr-mediated immune responses using adaptor oligonucleotides

Country Status (9)

Country Link
EP (1) EP1928500A2 (en)
JP (1) JP2009510096A (en)
KR (1) KR20080059595A (en)
CN (1) CN101340931A (en)
AU (1) AU2006294528A1 (en)
BR (1) BRPI0616770A2 (en)
CA (1) CA2623764A1 (en)
EA (1) EA200800943A1 (en)
WO (1) WO2007038720A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107919B2 (en) 2009-02-06 2015-08-18 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69932717T2 (en) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa METHODS AND PRODUCTS FOR INDUCING MUCOSAL IMMUNITY
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
SI1296714T1 (en) 2000-06-22 2010-01-29 S For Entpr University Of Iowa Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
BR0315810A (en) 2002-10-29 2005-09-13 Coley Pharmaceutical Group Ltd Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
EP1578954A4 (en) 2002-12-11 2010-08-11 Coley Pharm Group Inc 5' cpg nucleic acids and methods of use
ES2577514T3 (en) 2005-08-22 2016-07-15 The Regents Of The University Of California TLR antagonists
ES2544877T3 (en) 2005-10-12 2015-09-04 Idera Pharmaceuticals Immune Regulatory Oligonucleotide Compounds (IROs) to Modulate the Toll-Like Receptor-Based Immune Response
US8846697B2 (en) 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
US8377898B2 (en) 2006-10-12 2013-02-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
PT2510946E (en) 2007-02-07 2015-11-23 Univ California Conjugates of synthetic tlr agonists and uses therefor
AU2008326187B2 (en) * 2007-11-06 2014-12-04 Adiutide Pharmaceuticals Gmbh Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
US8853177B2 (en) 2008-10-06 2014-10-07 Idera Pharmaceuticals, Inc. Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto
EA019768B1 (en) 2009-02-11 2014-06-30 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Compounds modulating activity of toll-like receptors
US8987221B2 (en) 2009-06-01 2015-03-24 Idera Pharmaceuticals, Inc. Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (IRO) antagonists of TLR7 and TLR9
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
CA2797315C (en) 2010-04-30 2018-09-11 Telormedix Sa Phospholipid drug analogs
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
WO2019160866A2 (en) * 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
EP3775218A1 (en) 2018-04-09 2021-02-17 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
US11504425B2 (en) 2019-02-26 2022-11-22 Wayne State University Amphiphilic oligodeoxynucleotide conjugates as adjuvant enhancers
WO2021173832A1 (en) * 2020-02-25 2021-09-02 Bolt Biotherapeutics, Inc. Cancer treatment methods
CA3171986A1 (en) * 2020-05-19 2021-11-25 Michael Paul Marie Gantier Oligonucleotides
CN114588130B (en) * 2020-11-20 2023-07-04 四川好医生攀西药业有限责任公司 Adhesive bandage containing periplaneta americana active ingredient and preparation method thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022809A2 (en) * 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
US20030232074A1 (en) * 2002-04-04 2003-12-18 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US20050004144A1 (en) * 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
WO2005007672A2 (en) * 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (tlr) antagonists
US20050054590A1 (en) * 2003-09-05 2005-03-10 Averett Devron R. Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus
WO2005025614A2 (en) * 2003-09-15 2005-03-24 Glaxo Group Limited Improvements in vaccination
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022809A2 (en) * 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
US20030232074A1 (en) * 2002-04-04 2003-12-18 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US20050004144A1 (en) * 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
WO2005007672A2 (en) * 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (tlr) antagonists
US20050054590A1 (en) * 2003-09-05 2005-03-10 Averett Devron R. Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus
WO2005025583A2 (en) * 2003-09-05 2005-03-24 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
WO2005025614A2 (en) * 2003-09-15 2005-03-24 Glaxo Group Limited Improvements in vaccination
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AKIRA S: "Mammalian Toll-like receptors", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, vol. 15, no. 1, February 2003 (2003-02-01), pages 5 - 11, XP004399365, ISSN: 0952-7915 *
CHUANG T-H ET AL: "CLONING AND CHARACTERIZATION OF A SUB-FAMILY OF HUMAN TOLL-LIKE RECEPTORS: HTLR7, HTLR8 AND HTLR9", CHEMISCHE TECHNIK, LEIPZIG, DE, vol. 11, no. 3, September 2000 (2000-09-01), pages 372 - 378, XP009000971 *
DU X ET AL: "THREE NOVEL MAMMALIAN TOLL-LIKE RECEPTORS: GENE STRUCTURE, EXPRESSION, AND EVOLUTION", EUROPEAN CYTOKINE NETWORK, JOHN LIBBEY EUROTEXT LTD., MONTROUGE, FR, vol. 11, no. 3, September 2000 (2000-09-01), pages 362 - 371, XP009000972, ISSN: 1148-5493 *
JURK M ET AL: "HUMAN TLR7 OR TLR8 INDEPENDENTLY CONFER RESPONSIVENESS TO THE ANTIVIRAL COMPOUND R-848", NATURE IMMUNOLOGY, NATURE PUBLISHING GROUP,, GB, vol. 3, no. 6, June 2002 (2002-06-01), pages 499, XP009000821, ISSN: 1529-2908 *
WAGNER H: "Toll meets bacterial CpG-DNA", IMMUNITY, CELL PRESS, US, vol. 14, no. 5, May 2001 (2001-05-01), pages 499 - 502, XP002250852, ISSN: 1074-7613 *
WEERATNA ET AL: "TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 23, no. 45, 1 November 2005 (2005-11-01), pages 5263 - 5270, XP005115867, ISSN: 0264-410X *
WIEGEL B J ET AL: "CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomysarcoma", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. 8, 2003, pages 3105 - 3114, XP002990544, ISSN: 1078-0432 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107919B2 (en) 2009-02-06 2015-08-18 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration

Also Published As

Publication number Publication date
CN101340931A (en) 2009-01-07
BRPI0616770A2 (en) 2011-06-28
JP2009510096A (en) 2009-03-12
AU2006294528A1 (en) 2007-04-05
WO2007038720A2 (en) 2007-04-05
CA2623764A1 (en) 2007-04-05
EA200800943A1 (en) 2008-12-30
EP1928500A2 (en) 2008-06-11
KR20080059595A (en) 2008-06-30

Similar Documents

Publication Publication Date Title
WO2007038720A3 (en) Modulation of tlr-mediated immune responses using adaptor oligonucleotides
WO2006116458A3 (en) Modified oligoribonucleotide analogs with enhances immunostimulatory activity
WO2007042554A3 (en) Methods and compositions for treating immune disorders
EP1949333A4 (en) Multi-user terminal services accelerator
WO2009120893A3 (en) Polypeptide-polymer conjugates and methods of use thereof
WO2008142509A3 (en) Class a oligonucleotides with immunostimulatory potency
WO2006050477A3 (en) Anti-microbial compositions and methods of making and using the same
WO2007024612A3 (en) 8-substituted benzoazepines as toll-like receptor modulators
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2010054154A3 (en) Bifidobacteria crispr sequences
WO2006091915A3 (en) Immunostimulatory oligonucleotides
TWI318030B (en) Universal crimping connector
WO2010062396A3 (en) Virus like particle compositions and methods of use
WO2007064857A3 (en) Amphoteric liposome formulation
WO2007024705A3 (en) Method of treating depression using a tnf-alpha antibody
WO2006036916A3 (en) Rnai modulation of apob and uses thereof
WO2008131451A3 (en) Pva-paa hydrogels
WO2009018431A3 (en) Novel synthetic agonists of tlr9
MX2008008321A (en) Methods of making polymeric articles and the polymeric articles formed thereby.
WO2007040840A3 (en) Aminodiazepines as toll-like receptor modulators
WO2007033221A3 (en) Methods and compositions for inhibition of immune responses
WO2004080391A3 (en) Novel antibacterial agents
WO2008005358A3 (en) Novel macromolecular antioxidants comprising differing antioxidant moieties: structures, methods of making and using the same
WO2007144779A3 (en) Compositions comprising porphyra and methods of making and using thereof
WO2009002440A3 (en) Compositions comprising human egfr-sirna and methods of use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680044386.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 190392

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2623764

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/004141

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2008533635

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 566995

Country of ref document: NZ

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006836152

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2856/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006294528

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020087009932

Country of ref document: KR

Ref document number: 200800943

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2006294528

Country of ref document: AU

Date of ref document: 20060927

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06836152

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0616770

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080327